On July 4, UBS Group declared to the AMF that, through its subsidiaries, it had exceeded the threshold of 5% of Inventiva's capital and held, directly and indirectly, 5.16% of the capital and 4.14% of the voting rights of the biopharmaceutical company.

This threshold crossing is the result of an off-market acquisition of Inventiva shares, as a result of which the trading exemption no longer applies to the declarant", explains the Swiss financial institution.

Copyright (c) 2024 CercleFinance.com. All rights reserved.